knowledge -WSS

knowledge

author：hotspot 2025-09-29 17:01:58 - browse：7

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： John Green on his newest strategy for fighting tuberculosis

hotspot

WSS

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

How many hemophilia patients actually want gene therapy?

With FDA staff opposed to Sarepta therapy, top official intervened

CDC concerned about possible undetected monkeypox spread in U.K.

Steward Health Care Massachusetts hospitals face fiscal disaster

How many hemophilia patients actually want gene therapy?

explore

knowledge

explore

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

How one medical school became remarkably diverse

Why depression after traumatic brain injury is distinct

Hepatitis C has a cure — but many Americans still lack access to it

#NeedHerScience: shining a light on gender disparities in medicine

Anesthesiologist group: stop taking Ozempic before surgery

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Sports medicine is finally prioritizing gender equality

Ask STAT: What do you want to know about ChatGPT in medicine?

focus

First U.S. drug developed to treat liver disease MASH is approved

STAT's guide to the next generation of CAR

Ebola: Gilead Sciences antiviral shows promise as new treatment

RaDonda Vaught links Vanderbilt hospital issues to patient death

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

STAT's guide to the next generation of CAR

focus

focus

hotspot

entertainment